dorsaVi's new CFO to lay foundation for growth
Melbourne-based medical device company dorsaVi (ASX:DVL) has appointed Jerome Whelan as its new CFO.
Whelan joins dorsaVi from SapientNitro, where he held the post of Australian CFO. He has also held roles including US finance director of OMD and global finance director of FutureBrand.
He has experience in areas including financial operational management, corporate accounting, financial analysis, forecasting, change management, process redesign and new systems integration.
In his new role, Whelan said he aims to help "build the foundations on which we will deliver the strategies that underpin dorsaVi's international expansion".
dorsaVi develops motion analysis devices for use in sports, OHS, medical and physiotherapy applications. The company is in the process of increasing sales and marketing resources domestically and in the US and European markets.
The company’s ViPerform sports injury assessment device was recently listed with the US FDA. The product is already being used by AFL and NRL clubs in Australia, English Premier League Clubs, Cricket Australia, the AIS and various Olympic athletes.
In the OHS sphere, the company recently partnered with Australian insurer Allianz to promote the use of its ViSafe device in Australian workplaces.
dorsaVi (ASX:DVL) shares were trading unchanged at $0.48 as of around 2 pm on Thursday.
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
